UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Chagas disease in north-west Argentina: infected dogs as a risk factor for the domestic transmission of Trypanosoma cruzi

Transactions of the Royal Society of Tropical Medicine and Hygiene, 1991-11, Vol.85 (6), p.741-745

1991

Volltextzugriff (PDF)

Dynamics of transmission of Trypanosoma cruzi in a rural area of Argentina. I--The dog reservoir: an epidemiological profile

Revista do Instituto de Medicina Tropical de São Paulo, 1986-01, Vol.28 (1), p.28-35

1986

Volltextzugriff (PDF)

Dynamics of transmission of Trypanosoma cruzi in a rural area of Argentina. IV. Serologic, parasitologic and electrocardiographic study of the human population

Medicina (Buenos Aires), 1989, Vol.49 (4), p.341

1989

Volltextzugriff (PDF)

Prevalence of Trypanosoma cruzi infection in opossum (Didelphis albiventris) in Santiago del Estero, Argentina

Revista panamericana de salud pública, 1999-12, Vol.6 (6), p.371-377

1999

Volltextzugriff (PDF)

Dynamics of transmission of Trypanosoma cruzi in a rural area of Argentina: II. Household infection patterns among children and dogs relative to the density of infected Triatoma infestans

Bulletin of the Pan American Health Organization, 1987, Vol.21 (3), p.280

1987

Volltextzugriff (PDF)

Dynamics of transmission of Trypanosoma cruzi in a rural area of Argentina. I: The dog reservoir: an epiidemiological profile

Revista do Instituto de Medicina Tropical de São Paulo, 1986, Vol.28 (1), p.28-35

1986

Volltextzugriff (PDF)

Trypanosoma cruzi infection in humans, dogs and goats in rural areas of the province of Córdoba

Medicina (Buenos Aires), 1985, Vol.45 (5), p.539

1985

Volltextzugriff (PDF)

Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial

Diabetes, obesity & metabolism, 2017-12, Vol.19 (12), p.1781-1792

2017

Volltextzugriff (PDF)

Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial

Diabetes, obesity & metabolism, 2018-06, Vol.20 (6), p.1479-1489

2018

Volltextzugriff (PDF)

Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials

Diabetic medicine, 2018-12, Vol.35 (12), p.1742-1751

2018

Volltextzugriff (PDF)

Inter-gender differences of balance indicators in persons 60-90 years of age

Clinical interventions in aging, 2018-01, Vol.13, p.903-912

2018

Volltextzugriff (PDF)

Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies

Cardiovascular diabetology, 2019-11, Vol.18 (1), p.149-10, Article 149

2019

Volltextzugriff (PDF)

Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels

Clinical therapeutics, 2015-09, Vol.37 (9), p.1945-1954.e6

2015

Volltextzugriff (PDF)

Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial

Atherosclerosis, 2018-09, Vol.276, p.124-130

2018

Volltextzugriff (PDF)

SHORT-DURATION, VERY HIGH-INTENSITY LIPID-LOWERING THERAPY RESULTS IN PROLONGED REDUCTION OF CARDIOVASCULAR EVENTS FOLLOWING ACUTE CORONARY SYNDROME

Journal of the American College of Cardiology, 2023-03, Vol.81 (8), p.1627-1627

2023

Volltextzugriff (PDF)

Interactive and Dynamic Graphics for Data Analysis: With R and GGobi

1. Aufl., 2007

Volltextzugriff (PDF)

Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM–INSULIN trial

Diabetes & metabolism, 2017-10, Vol.43 (5), p.453-459

2017

Volltextzugriff (PDF)

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk

Cardiovascular diabetology, 2017-05, Vol.16 (1), p.70-70, Article 70

2017

Volltextzugriff (PDF)

Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin

The journal of clinical endocrinology and metabolism, 2019-11, Vol.104 (11), p.5253-5262

2019

Volltextzugriff (PDF)

A CROSS-SECTIONAL SURVEY OF CARDIOMETABOLIC RISK FACTORS IN PRIMARY CARE PATIENTS WITH ABDOMINAL OBESITY IN CANADA

Canadian journal of cardiology, 2014-10, Vol.30 (10), p.S310-S311

2014

Volltextzugriff (PDF)

EXAGGERATED CARDIOMETABOLIC RISK FACTORS AND CARDIOVASCULAR DISEASE IN CANADIAN PRIMARY CARE PATIENTS WITH DIABETES AND ABDOMINAL OBESITY

Canadian journal of cardiology, 2014-10, Vol.30 (10), p.S304-S304

2014

Volltextzugriff (PDF)

Abstract 17070: Efficacy and Safety of Alirocumab: Pooled Analyses of 1048 Individuals With Diabetes Mellitus From Five Placebo-controlled Phase 3 Studies of at Least 52 Weeks Duration

Circulation (New York, N.Y.), 2015-11, Vol.132 (Suppl_3 Suppl 3), p.A17070-A17070

2015

Volltextzugriff (PDF)

Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial

Diabetes, obesity & metabolism, 2018-02

2018

Volltextzugriff (PDF)

Diagnosis, management, and outcomes of patients with syncope and bundle branch block

European heart journal, 2011-06, Vol.32 (12), p.1535-1541

2011

Volltextzugriff (PDF)

Lack of phencyclidine-induced effects in mice with reduced neuronal nitric oxide synthase

Psychopharmacologia, 2001-05, Vol.155 (3), p.299-309

2001

Volltextzugriff (PDF)

1 – 25 von 125

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(90)
Mit Volltextzugriff
(81)

Publikationsform

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(44)
Female
(41)
Science & Technology
(32)
Male
(31)
Life Sciences & Biomedicine
(30)
Adult
(18)
Biological And Medical Sciences
(18)
Animals
(17)
Middle Aged
(14)
Medical Sciences
(12)
Aged
(10)
Rats
(10)
Immunology
(9)
Neurosciences
(9)
Neurosciences & Neurology
(9)
Pathology
(9)
Physiology
(9)
Psychology. Psychoanalysis. Psychiatry
(9)
Adolescent
(8)
Diabetes
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Chagas disease in north-west Argentina: infected dogs as a risk factor for the domestic transmission of Trypanosoma cruzi

Dynamics of transmission of Trypanosoma cruzi in a rural area of Argentina. I--The dog reservoir: an epidemiological profile

Dynamics of transmission of Trypanosoma cruzi in a rural area of Argentina. IV. Serologic, parasitologic and electrocardiographic study of the human population

Prevalence of Trypanosoma cruzi infection in opossum (Didelphis albiventris) in Santiago del Estero, Argentina

Dynamics of transmission of Trypanosoma cruzi in a rural area of Argentina: II. Household infection patterns among children and dogs relative to the density of infected Triatoma infestans

Dynamics of transmission of Trypanosoma cruzi in a rural area of Argentina. I: The dog reservoir: an epiidemiological profile

Trypanosoma cruzi infection in humans, dogs and goats in rural areas of the province of Córdoba

Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial

Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial

Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials

Inter-gender differences of balance indicators in persons 60-90 years of age

Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies

Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels

Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial

SHORT-DURATION, VERY HIGH-INTENSITY LIPID-LOWERING THERAPY RESULTS IN PROLONGED REDUCTION OF CARDIOVASCULAR EVENTS FOLLOWING ACUTE CORONARY SYNDROME

Interactive and Dynamic Graphics for Data Analysis: With R and GGobi

Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM–INSULIN trial

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk

Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin

A CROSS-SECTIONAL SURVEY OF CARDIOMETABOLIC RISK FACTORS IN PRIMARY CARE PATIENTS WITH ABDOMINAL OBESITY IN CANADA

EXAGGERATED CARDIOMETABOLIC RISK FACTORS AND CARDIOVASCULAR DISEASE IN CANADIAN PRIMARY CARE PATIENTS WITH DIABETES AND ABDOMINAL OBESITY

Abstract 17070: Efficacy and Safety of Alirocumab: Pooled Analyses of 1048 Individuals With Diabetes Mellitus From Five Placebo-controlled Phase 3 Studies of at Least 52 Weeks Duration

Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial

Diagnosis, management, and outcomes of patients with syncope and bundle branch block

Lack of phencyclidine-induced effects in mice with reduced neuronal nitric oxide synthase

Suchergebnisse filtern